semaglutide and cardiovascular outcomes in obesity without diabetes journal club GLP-1 receptor agonists can reduce the risk of adverse events pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or Some reassuring data for #semaglutide

These proinflammatory cytokines recruit macrophages and neutrophils, intensifying inflammation and exacerbating liver injury, ultimately progressing to acute liver failure

These improvements translate to life-changing benefits: Some patients moved from severe to mild OSA Many saw complete symptom resolution Some no longer needed their CPAP machines after significant weight loss The FDAs approval of tirzepatide specifically for OSA in obese adults confirms these benefits

Management: Rotate injection sites regularly

Like any shot, you may feel a slight pinch, but the discomfort is minimal

longum 35624

The project number is 201901D111383